• 1. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 2. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 3. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 4. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 5. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzisoxazoles

3-Bromo-1,2-benzoxazol-7-ol: A Comprehensive Overview (CAS No. 1782249-69-7)

3-Bromo-1,2-benzoxazol-7-ol (CAS No. 1782249-69-7) is a unique and versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its bromine-substituted benzoxazole scaffold, exhibits a range of biological activities that make it a valuable candidate for various therapeutic applications. In this comprehensive overview, we will delve into the chemical properties, synthesis methods, biological activities, and potential applications of 3-Bromo-1,2-benzoxazol-7-ol.

Chemical Properties and Structure:

3-Bromo-1,2-benzoxazol-7-ol is a heterocyclic compound with the molecular formula C₈H₅BrNO₂. The molecule features a benzoxazole core with a bromine atom at the 3-position and a hydroxyl group at the 7-position. The presence of these functional groups imparts unique chemical and physical properties to the compound. The bromine substituent enhances the lipophilicity of the molecule, which can influence its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME). The hydroxyl group can participate in hydrogen bonding interactions, which may affect the compound's solubility and binding affinity to biological targets.

Synthesis Methods:

The synthesis of 3-Bromo-1,2-benzoxazol-7-ol has been explored through various synthetic routes. One common approach involves the reaction of 3-bromobenzoic acid with urea or thiourea to form the corresponding benzamide or benzothioamide intermediate. This intermediate is then cyclized under acidic conditions to yield the desired benzoxazole derivative. Another method involves the condensation of 3-bromobenzaldehyde with urea or thiourea followed by cyclization. These synthetic strategies provide flexible pathways for the preparation of 3-Bromo-1,2-benzoxazol-7-ol, allowing for the introduction of various substituents at different positions on the benzoxazole ring.

Biological Activities:

3-Bromo-1,2-benzoxazol-7-ol has demonstrated a range of biological activities that make it an attractive candidate for drug development. Recent studies have shown that this compound exhibits potent antitumor activity against various cancer cell lines. For instance, research published in the Journal of Medicinal Chemistry reported that 3-Bromo-1,2-benzoxazol-7-ol selectively inhibits the growth of breast cancer cells by inducing apoptosis and cell cycle arrest. The mechanism of action involves the modulation of key signaling pathways such as PI3K/AKT and MAPK/ERK.

In addition to its antitumor properties, 3-Bromo-1,2-benzoxazol-7-ol has also shown promise in neurodegenerative disease models. Studies have indicated that this compound can protect neurons from oxidative stress and inhibit neuroinflammation. These findings suggest that 3-Bromo-1,2-benzoxazol-7-ol may have therapeutic potential in conditions such as Alzheimer's disease and Parkinson's disease.

Potential Applications:

The diverse biological activities of 3-Bromo-1,2-benzoxazol-7-ol have led to its exploration in several therapeutic areas. In oncology, this compound is being investigated as a potential lead molecule for the development of novel anticancer agents. Its ability to selectively target cancer cells while sparing normal cells makes it an attractive candidate for chemotherapy. Preclinical studies have shown promising results in both in vitro and in vivo models.

In neurology, 3-Bromo-1,2-benzoxazol-7-ol-1,2-benzoxazol-7-ol) is being evaluated for its neuroprotective effects in preclinical models of neurodegenerative diseases. Its ability to reduce oxidative stress and inflammation suggests that it may be beneficial in slowing disease progression and improving patient outcomes.

Beyond oncology and neurology, there is growing interest in exploring the potential applications of ^{_{<code></code></small></mark>^{_{<s><u><i><b><em></b></i></u></s>}}</mark><small>?&nbsp;?&nbsp;?&nbsp;?&nbsp;?&nbsp;?&nbsp;?&nbsp;?&nbsp;?(CAS No.&nbsp;1782249&ndash;69&ndash;7)}})>>) in other therapeutic areas such as anti-inflammatory and anti-viral treatments.. For example, preliminary studies have suggested that this compound may have anti-inflammatory properties by inhibiting pro-inflammatory cytokines such as TNF-alpha and IL-6.

In conclusion,(CAS No.&nbsp;1782249&ndash;69&ndash;7)) is a promising compound with a wide range of biological activities that make it a valuable candidate for drug development. Its unique chemical structure and versatile biological profile position it as a potential lead molecule for various therapeutic applications. Ongoing research continues to uncover new insights into its mechanisms of action and potential clinical uses..

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)